Phacilitate Leaders World 

Patient Access and Delivery of Advanced Therapies - Part Two

Patient Access and Delivery of Advanced Therapies - Part Two

An Interview with Dr. Matthew Frigault, Instructor and Clinical Assistant in Medicine, Massachusetts General Hospital

Dr Matthew Frigault, Instructor and Clinical Assistant in Medicine at Massachusetts General Hospital, gives the clinician’s perspective on patient access and delivery of advanced therapies and answers four crucial questions:

  1. Are specific centres of excellence the answer to improving patient access to advanced therapies and clinical trials?
  2. Is the next generation of cellular immunotherapies agnostic?
  3. Can you share some of the cellular immunotherapy initiatives going on at Mass General Cancer Center?
  4. What role, if any, can clinicians play in working with payers to secure funding for ATMPs?

 


 

Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK